Shares of vaccine specialist Vaxart have exploded an astonishing 4748% so far this year, as investors have piled into the company on the hopes that it – and its “one-of-its-kind” oral solution vaccine platform – could be the ultimate deliverer of a successful COVID-19 vaccine. And despite this massive move higher, one 5-star analyst believes that the stock still has plenty of room to run. For more, CLICK HERE.